低密度脂蛋白胆固醇目标在心血管二级预防中的有效性。

IF 4.4 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL European Journal of Clinical Investigation Pub Date : 2024-06-03 DOI:10.1111/eci.14258
Maria Garcia-Gil, Lia Alves-Cabratosa, Oriol Cunillera, Jordi Blanch, Ruth Martí-Lluch, Anna Ponjoan, Francesc Ribas-Aulinas, Èric Tornabell-Noguera, Lluís Zacarías-Pons, Gina Domínguez-Armengol, Elizabeth Guzmán, Rafel Ramos
{"title":"低密度脂蛋白胆固醇目标在心血管二级预防中的有效性。","authors":"Maria Garcia-Gil,&nbsp;Lia Alves-Cabratosa,&nbsp;Oriol Cunillera,&nbsp;Jordi Blanch,&nbsp;Ruth Martí-Lluch,&nbsp;Anna Ponjoan,&nbsp;Francesc Ribas-Aulinas,&nbsp;Èric Tornabell-Noguera,&nbsp;Lluís Zacarías-Pons,&nbsp;Gina Domínguez-Armengol,&nbsp;Elizabeth Guzmán,&nbsp;Rafel Ramos","doi":"10.1111/eci.14258","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The effectiveness of statin treatment to reduce coronary events and mortality has been hardly examined considering goals of LDL-C. We aimed to analyse such association in secondary cardiovascular prevention.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Retrospective cohort analysis of electronic health records from the SIDIAP database, Catalonia-Spain. Recruitment period was from 2006 to 2017 and study period finished at the end of 2018. We included 54,175 people aged ≥35 years in cardiovascular secondary prevention starting statin treatment. We analysed the association of achieved LDL-C goals after statin initiation with coronary heart disease and all-cause mortality.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Mean age was 69 years and 20,146 (37.2%) were women. Coronary heart disease occurred in 5687 (10.5%) participants, and 10,676 (19.7%) persons passed away. Median follow-up lasted 5.7 years (interquartile range, 3.4–8.1). The coronary heart disease HRs (95% CI) for the LDL-C goals of 70–100, &lt;70–55 and &lt;55 mg/dL were .86 (.81–.92), .83 (.76–.9) and .8 (.72–.88), respectively. They were .89 (.83–.96) in the group with 30%–40% reduction and .86 (.8–.93) in the groups with 40%–50% and ≥50% reduction. We observed no association with mortality. We observed no relevant differences by sex or age.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This population-level retrospective analysis of real-world data observed that treatment with statins is effective to achieve certain LDL-C goals and CHD reduction. The lack of significant difference between LDL-C goals needs confirmation in additional studies with real-world data. The LDL-C target should consider the magnitude of the decrease in coronary events.</p>\n </section>\n </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"54 9","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.14258","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of the low-density lipoprotein cholesterol goals in secondary cardiovascular prevention\",\"authors\":\"Maria Garcia-Gil,&nbsp;Lia Alves-Cabratosa,&nbsp;Oriol Cunillera,&nbsp;Jordi Blanch,&nbsp;Ruth Martí-Lluch,&nbsp;Anna Ponjoan,&nbsp;Francesc Ribas-Aulinas,&nbsp;Èric Tornabell-Noguera,&nbsp;Lluís Zacarías-Pons,&nbsp;Gina Domínguez-Armengol,&nbsp;Elizabeth Guzmán,&nbsp;Rafel Ramos\",\"doi\":\"10.1111/eci.14258\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>The effectiveness of statin treatment to reduce coronary events and mortality has been hardly examined considering goals of LDL-C. We aimed to analyse such association in secondary cardiovascular prevention.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Retrospective cohort analysis of electronic health records from the SIDIAP database, Catalonia-Spain. Recruitment period was from 2006 to 2017 and study period finished at the end of 2018. We included 54,175 people aged ≥35 years in cardiovascular secondary prevention starting statin treatment. We analysed the association of achieved LDL-C goals after statin initiation with coronary heart disease and all-cause mortality.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Mean age was 69 years and 20,146 (37.2%) were women. Coronary heart disease occurred in 5687 (10.5%) participants, and 10,676 (19.7%) persons passed away. Median follow-up lasted 5.7 years (interquartile range, 3.4–8.1). The coronary heart disease HRs (95% CI) for the LDL-C goals of 70–100, &lt;70–55 and &lt;55 mg/dL were .86 (.81–.92), .83 (.76–.9) and .8 (.72–.88), respectively. They were .89 (.83–.96) in the group with 30%–40% reduction and .86 (.8–.93) in the groups with 40%–50% and ≥50% reduction. We observed no association with mortality. We observed no relevant differences by sex or age.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>This population-level retrospective analysis of real-world data observed that treatment with statins is effective to achieve certain LDL-C goals and CHD reduction. The lack of significant difference between LDL-C goals needs confirmation in additional studies with real-world data. The LDL-C target should consider the magnitude of the decrease in coronary events.</p>\\n </section>\\n </div>\",\"PeriodicalId\":12013,\"journal\":{\"name\":\"European Journal of Clinical Investigation\",\"volume\":\"54 9\",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.14258\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Clinical Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/eci.14258\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/eci.14258","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:考虑到低密度脂蛋白胆固醇(LDL-C)的目标,他汀类药物治疗在减少冠心病事件和死亡率方面的有效性几乎没有得到研究。我们旨在分析心血管二级预防中的这种关联:方法:对西班牙加泰罗尼亚地区 SIDIAP 数据库中的电子健康记录进行回顾性队列分析。招募期为 2006 年至 2017 年,研究期于 2018 年底结束。我们纳入了 54175 名年龄≥35 岁、开始接受他汀类药物治疗的心血管二级预防患者。我们分析了他汀类药物起始后达到低密度脂蛋白胆固醇目标与冠心病和全因死亡率的关系:平均年龄为 69 岁,20146 人(37.2%)为女性。5687人(10.5%)罹患冠心病,10676人(19.7%)去世。中位随访时间为 5.7 年(四分位间范围为 3.4-8.1 年)。低密度脂蛋白胆固醇(LDL-C)目标值为 70-100 的冠心病 HRs(95% CI):这项对真实世界数据进行的人群水平回顾性分析观察到,他汀类药物治疗能有效达到一定的低密度脂蛋白胆固醇目标并减少冠心病发病率。不同低密度脂蛋白胆固醇目标之间没有明显差异,这需要更多的真实世界数据研究来证实。低密度脂蛋白胆固醇目标应考虑冠心病事件减少的幅度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Effectiveness of the low-density lipoprotein cholesterol goals in secondary cardiovascular prevention

Background

The effectiveness of statin treatment to reduce coronary events and mortality has been hardly examined considering goals of LDL-C. We aimed to analyse such association in secondary cardiovascular prevention.

Methods

Retrospective cohort analysis of electronic health records from the SIDIAP database, Catalonia-Spain. Recruitment period was from 2006 to 2017 and study period finished at the end of 2018. We included 54,175 people aged ≥35 years in cardiovascular secondary prevention starting statin treatment. We analysed the association of achieved LDL-C goals after statin initiation with coronary heart disease and all-cause mortality.

Results

Mean age was 69 years and 20,146 (37.2%) were women. Coronary heart disease occurred in 5687 (10.5%) participants, and 10,676 (19.7%) persons passed away. Median follow-up lasted 5.7 years (interquartile range, 3.4–8.1). The coronary heart disease HRs (95% CI) for the LDL-C goals of 70–100, <70–55 and <55 mg/dL were .86 (.81–.92), .83 (.76–.9) and .8 (.72–.88), respectively. They were .89 (.83–.96) in the group with 30%–40% reduction and .86 (.8–.93) in the groups with 40%–50% and ≥50% reduction. We observed no association with mortality. We observed no relevant differences by sex or age.

Conclusions

This population-level retrospective analysis of real-world data observed that treatment with statins is effective to achieve certain LDL-C goals and CHD reduction. The lack of significant difference between LDL-C goals needs confirmation in additional studies with real-world data. The LDL-C target should consider the magnitude of the decrease in coronary events.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.50
自引率
3.60%
发文量
192
审稿时长
1 months
期刊介绍: EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
期刊最新文献
Ceramide and phosphatidylcholine lipids-based risk score predicts major cardiovascular outcomes in patients with heart failure. Issue Information [225Ac]Ac-PSMA for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. Machine learning for stroke in heart failure with reduced ejection fraction but without atrial fibrillation: A post-hoc analysis of the WARCEF trial. Structural aspects of CEACAM1 interactions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1